Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: ARIA
CUSIP: 04033A10

Key Metrics:

Previous Close: $13.63
50 Day Moving Average: $10.83
200 Day Moving Average: $8.29
52-Week Range: $4.37 - $13.94
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -21.13
P/E Growth: -5.05
Market Cap: $2.61B
Outstanding Shares: 192,713,000
Beta: 1.92

Profitability:

Net Margins: -35.00%
Return on Assets: -10.26%

Debt:

Debt-to-Equity Ratio: -12.32%
Current Ratio: 3.05%
Quick Ratio: 3.04%

Additional Links:

Companies Related to Ariad Pharmaceuticals:

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)

Ratings Breakdown:	1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:	Buy (Score: 2.57)
Consensus Price Target:	$9.29 (31.32% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)

Show:

Date	Firm	Action	Rating	Price Target
7/31/2016	Cowen and Company	Reiterated Rating	Outperform	$10.00
7/29/2016	Jefferies Group	Reiterated Rating	Buy	$13.00
7/29/2016	Barclays PLC	Boost Price Target	Underweight	$8.00 -> $9.00
6/20/2016	Royal Bank Of Canada	Reiterated Rating	Hold
6/6/2016	JMP Securities	Reiterated Rating	Buy
5/24/2016	William Blair	Reiterated Rating	Buy	$10.00
3/11/2016	JPMorgan Chase & Co.	Reiterated Rating	Outperform	$11.00 -> $9.00
2/22/2016	Goldman Sachs Group Inc.	Lower Price Target		$7.00 -> $5.00
6/5/2015	HC Wainwright	Reiterated Rating	Buy
5/16/2015	BMO Capital Markets	Reiterated Rating	Outperform	$14.00
5/16/2015	Stifel Nicolaus	Reiterated Rating	Buy
12/11/2014	Credit Suisse Group AG	Downgrade	Neutral -> Underperform	$8.00 -> $6.00
11/6/2014	Chardan Capital	Reiterated Rating	Neutral

(Data available from 9/24/2014 forward)

Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2016
7/28/2016	Q216	($0.11)	$0.59	$60.64 million	$65.30 million	View	Listen
5/10/2016	Q116	($0.27)	($0.23)	$43.06 million	$35.60 million	View	Listen
2/23/2016	Q415	($0.32)	($0.32)	$44.79 million	$36.50 million	View	Listen
11/3/2015	Q315	($0.23)	($0.29)	$46.09 million	$27.50 million	View	Listen
8/5/2015	Q215	($0.27)	($0.33)	$33.24 million	$27.80 million	View	Listen
5/7/2015	Q115	($0.27)	($0.28)	$27.26 million	$23.90 million	View	Listen
2/19/2015	Q414	($0.20)	($0.03)	$39.50 million	$66.00 million	View	Listen
11/5/2014	Q314	$0.30	($0.27)	$16.50 million	$14.70 million	View	Listen
8/6/2014	Q214	($0.29)	($0.30)	$13.65 million	$12.10 million	View	Listen
5/7/2014	Q114	($0.32)	($0.27)	$10.41 million	$11.80 million	View	Listen
2/25/2014	Q413	($0.47)	($0.40)	$6.31 million	$8.28 million	View	Listen
11/6/2013	Q313	($0.43)	($0.36)	$16.67 million	$16.70 million	View	Listen
8/7/2013	Q2 2013	($0.40)	($0.37)	$11.11 million	$13.90 million	View	Listen
5/7/2013	Q1 2013	($0.38)	($0.36)	$5.01 million	$6.40 million	View	Listen
2/25/2013	Q4 2012	($0.36)	($0.36)	$78.00 million	$0.07 million	View	Listen
11/7/2012	Q312	($0.32)	($0.32)	$0.96 million	$0.85 million	View	N/A
8/2/2012		($0.27)	($0.31)			View	N/A
5/9/2012		($0.23)	($0.35)			View	N/A
2/28/2012		($0.20)	($0.38)			View	N/A
11/3/2011		$0.02	$0.10			View	N/A
8/2/2011		($0.16)	($0.36)			View	N/A
5/5/2011		($0.13)	($0.29)			View	N/A
2/17/2011		($0.14)	($0.25)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)

Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	3	($0.34)	($0.17)	($0.27)
Q2 2016	2	($0.11)	($0.09)	($0.10)
Q3 2016	2	($0.22)	($0.21)	($0.22)
Q4 2016	2	($0.18)	($0.18)	($0.18)

(Data provided by Zacks Investment Research)

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 71.99%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/22/2016	Timothy P Clackson	Insider	Sell	20,000	$13.43	$268,600.00
9/15/2016	Timothy P Clackson	Insider	Sell	59,369	$11.73	$696,398.37
8/22/2016	Timothy P Clackson	Insider	Sell	19,436	$10.47	$203,494.92
8/12/2016	Timothy P Clackson	Insider	Sell	25,000	$10.50	$262,500.00
7/22/2016	Timothy P Clackson	Insider	Sell	18,286	$8.11	$148,299.46
6/28/2016	Hugh M Cole	SVP	Sell	6,012	$7.05	$42,384.60
6/22/2016	Timothy P Clackson	Insider	Sell	23,999	$7.28	$174,712.72
6/15/2016	Athanese Lavidas	Director	Sell	76,250	$8.21	$626,012.50
6/14/2016	Massimo Radaelli	Director	Sell	108,569	$8.25	$895,694.25
5/23/2016	Timothy P Clackson	Insider	Sell	17,762	$8.08	$143,516.96
5/12/2016	Paris Panayiotopoulos	CEO	Buy	26,990	$7.41	$199,995.90
5/2/2016	Timothy P Clackson	Insider	Sell	11,700	$7.13	$83,421.00
4/22/2016	Timothy P Clackson	Insider	Sell	21,409	$7.37	$157,784.33
3/22/2016	Timothy P Clackson	Insider	Sell	23,834	$6.58	$156,827.72
3/21/2016	David L Berstein	SVP	Sell	2,375	$6.47	$15,366.25
3/21/2016	Edward M Fitzgerald	VP	Sell	5,417	$6.47	$35,047.99
3/21/2016	Frank Haluska	CMO	Sell	3,575	$6.47	$23,130.25
3/19/2016	Maria E Cantor	SVP	Sell	3,575	$6.46	$23,094.50
3/19/2016	Martin J Duvall	EVP	Sell	4,000	$6.47	$25,880.00
3/19/2016	Timothy P Clackson	Insider	Sell	5,417	$6.47	$35,047.99
3/3/2016	Daniel M Bollag	VP	Sell	9,625	$6.11	$58,808.75
3/3/2016	Frank Haluska	CMO	Sell	10,588	$6.11	$64,692.68
3/3/2016	Timothy P Clackson	Insider	Sell	34,672	$6.03	$209,072.16
2/1/2016	Edward M. Fitzgerald	CFO	Sell	14,667	$4.81	$70,548.27
2/1/2016	Maria E. Cantor	SVP	Sell	16,133	$4.82	$77,761.06
2/1/2016	Paris Panayiotopoulos	CEO	Buy	61,099	$4.91	$299,996.09
9/28/2015	David L. Berstein	SVP	Sell	5,000	$6.46	$32,300.00
9/28/2015	Frank Haluska	CMO	Sell	5,500	$6.46	$35,530.00
9/28/2015	Timothy P. Clackson	insider	Sell	8,750	$6.46	$56,525.00
9/1/2015	Maria E Cantor	SVP	Sell	2,696	$9.11	$24,560.56
8/28/2015	Edward M Fitzgerald	CFO	Sell	32,858	$10.00	$328,580.00
8/28/2015	Maria E Cantor	SVP	Sell	1,268	$10.00	$12,680.00
7/16/2015	David L Berstein	SVP	Sell	4,000	$8.54	$34,160.00
7/16/2015	Edward M Fitzgerald	CFO	Sell	7,000	$8.54	$59,780.00
7/16/2015	Frank Haluska	CMO	Sell	4,400	$8.54	$37,576.00
7/16/2015	Martin J Duvall	EVP	Sell	1,400	$8.54	$11,956.00
5/1/2015	Edward M Fitzgerald	CFO	Sell	60,000	$8.80	$528,000.00
4/23/2015	Timothy P Clackson	Insider	Sell	123,766	$9.50	$1,175,777.00
3/23/2015	Daniel M Bollag	VP	Sell	7,000	$8.72	$61,040.00
3/23/2015	Edward M Fitzgerald	CFO	Sell	9,584	$8.72	$83,572.48
3/23/2015	Frank Haluska	CMO	Sell	6,875	$8.71	$59,881.25
3/23/2015	Maria E Cantor	SVP	Sell	16,954	$8.86	$150,212.44
3/23/2015	Martin J Duvall	EVP	Sell	4,834	$8.80	$42,539.20
3/23/2015	Timothy P Clackson	Insider	Sell	32,741	$8.88	$290,740.08
2/12/2015	Harvey J M D Berger	CEO	Buy	25,000	$6.83	$170,750.00
2/2/2015	Frank Haluska	CMO	Sell	16,134	$6.33	$102,128.22
1/23/2015	Harvey J M D Berger	CEO	Buy	25,000	$6.17	$154,250.00
1/14/2015	Sarah J Schlesinger	Director	Buy	2,600	$6.61	$17,186.00
12/18/2014	Harvey J M D Berger	CEO	Buy	25,000	$6.35	$158,750.00
12/17/2014	Sarah J Schlesinger	Director	Buy	2,600	$6.09	$15,834.00
11/24/2014	Maria E Cantor	SVP	Sell	1,749	$7.00	$12,243.00
11/20/2014	Harvey J M D Berger	CEO	Buy	25,000	$6.15	$153,750.00
11/12/2014	Sarah J Schlesinger	Director	Buy	2,600	$6.26	$16,276.00
9/10/2014	Sarah J Schlesinger	Director	Buy	5,200	$5.73	$29,796.00
8/15/2014	Alexander J Denner	Director	Buy	850,000	$5.83	$4,955,500.00
4/2/2014	Daniel Bollag	VP	Sell	2,400	$8.22	$19,728.00
4/2/2014	Frank Haluska	CMO	Sell	3,400	$8.21	$27,914.00
4/2/2014	Maria Cantor	SVP	Sell	4,250	$8.21	$34,892.50
4/2/2014	Timothy Clackson	Insider	Sell	6,500	$8.21	$53,365.00
3/21/2014	Daniel Bollag	VP	Sell	2,400	$7.89	$18,936.00
3/21/2014	David Berstein	SVP	Sell	1,600	$7.89	$12,624.00
3/21/2014	Timothy Clackson	Insider	Sell	6,667	$7.89	$52,602.63
12/19/2013	David Berstein	VP	Sell	4,500	$5.14	$23,130.00
12/19/2013	Frank Haluska	CMO	Sell	5,100	$5.14	$26,214.00
12/19/2013	Maria Cantor	SVP	Sell	6,375	$5.14	$32,767.50
12/19/2013	Timothy Clackson	Insider	Sell	9,750	$5.14	$50,115.00
9/6/2013	Timothy P Clackson	Insider	Sell	8,449	$22.00	$185,878.00
8/14/2013	Harvey Berger	CEO	Sell	118,759	$18.34	$2,178,040.06
7/18/2013	Frank Haluska	CMO	Sell	6,400	$19.79	$126,656.00
7/18/2013	Maria E Cantor	SVP	Sell	8,000	$19.79	$158,320.00
7/18/2013	Timothy P Clackson	Insider	Sell	14,000	$19.79	$277,060.00
7/17/2013	Harvey J M D Berger	CEO	Sell	199,400	$19.84	$3,956,096.00
6/19/2013	Harvey J M D Berger	CEO	Sell	11,200	$18.00	$201,600.00
5/15/2013	Harvey J M D Berger	CEO	Sell	92,498	$18.10	$1,674,213.80
3/26/2013	Edward M Fitzgerald	CFO	Sell	12,933	$18.75	$242,493.75
3/25/2013	Daniel M Bollag	VP	Sell	12,933	$18.87	$244,045.71
3/25/2013	Frank Haluska	CMO	Sell	5,333	$18.88	$100,687.04
3/25/2013	Pierre F Dodion	SVP	Sell	8,133	$18.87	$153,469.71
3/25/2013	Timothy P Clackson	Insider	Sell	19,167	$18.87	$361,681.29
3/13/2013	Harvey J M D Berger	CEO	Sell	105,400	$22.05	$2,324,070.00
12/21/2012	Athanese Lavidas	Director	Sell	10,500	$20.31	$213,255.00

(Data available from 1/1/2013 forward)

Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)

Date	Headline
	Ariad Shares Rise Amid Speculation of Potential Buyout (NASDAQ:ARIA) myhealthbowl.com - September 24 at 3:31 PM
	Eye Catching Insider Trading: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 24 at 8:54 AM
	How trader is showing support for Ariad (NASDAQ:ARIA) finance.yahoo.com - September 23 at 8:24 AM
	Time To Put On The Watch List? - Nektar Therapeutics (NASDAQ:NKTR), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 22 at 3:32 PM
	Ariad Receives Interest as a Buyout Candidate (NASDAQ:ARIA) www.investopedia.com - September 22 at 3:32 PM
	Biotech news that matter for investors: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Conatus Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 21 at 4:29 PM
	Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) To Report September 2016 Results - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 21 at 4:29 PM
	4 health-care stocks to watch (NASDAQ:ARIA) www.marketwatch.com - September 21 at 4:29 PM
	HC Stocks in Top Row! Ariad Pharmaceuticals, Inc. (ARIA), Northwest Biotherapeutics, Inc (NASDAQ:NWBO) - share market updates (press release) (NASDAQ:ARIA) sharemarketupdates.com - September 21 at 8:49 AM
	Ariad Shares Rise Amid Speculation of Potential Buyout - Bloomberg (NASDAQ:ARIA) www.bloomberg.com - September 21 at 8:49 AM
	Ariad Pharma (ARIA) Stock Surged Today on Takeover Speculation (NASDAQ:ARIA) www.thestreet.com - September 21 at 8:49 AM
	Trader's Buzzer: PayPal Holdings, Inc. (NASDAQ:PYPL), ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Newburgh Press (NASDAQ:ARIA) newburghpress.com - September 20 at 3:33 PM
	Biotech Stocks Worth a Closer Look: Radius Health, Inc. (NASDAQ:RDUS), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 20 at 3:33 PM
	HC Stocks Reports Analysis! Ariad Pharmaceuticals, Inc. (ARIA), Abbott Laboratories (NYSE:ABT) - share market updates (press release) (NASDAQ:ARIA) sharemarketupdates.com - September 20 at 3:33 PM
	Overbuying Alert on: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - Post Registrar (NASDAQ:ARIA) postregistrar.com - September 20 at 3:33 PM
	Ariad Shares Rise Amid Speculation of Buyout Target Potential (NASDAQ:ARIA) finance.yahoo.com - September 20 at 3:33 PM
	How Ionis Pharmaceuticals’ Valuation Compares to Its Peers (NASDAQ:ARIA) marketrealist.com - September 20 at 3:33 PM
	Ariad Pharmaceuticals Inc. (ARIA) Insider Sells $696,398.37 in Stock (NASDAQ:ARIA) www.bioportfolio.com - September 19 at 4:29 PM
	Ariad Pharmaceuticals (ARIA) Stock Is Monday's 'Chart of the Day' (NASDAQ:ARIA) www.thestreet.com - September 19 at 4:29 PM
	HC Stocks News! Ariad Pharmaceuticals, Inc. (ARIA), Northwest Biotherapeutics, Inc (NASDAQ:NWBO) - share market updates (press release) (NASDAQ:ARIA) sharemarketupdates.com - September 16 at 3:35 PM
	Put seller betting Ariad will hold gains (NASDAQ:ARIA) finance.yahoo.com - September 16 at 12:15 PM
	ARIAD Pharma (ARIA) to Make Several Iclusig Presentation at John Goldman Conference - StreetInsider.com (NASDAQ:ARIA) www.streetinsider.com - September 15 at 8:42 PM
	ARIAD Pharmaceuticals Reaches Analyst Target Price - Forbes (NASDAQ:ARIA) www.forbes.com - September 15 at 8:42 PM
	Ariad Pharmaceuticals Shares Up 36.5% Since SmarTrend's Buy Recommendation (ARIA) (NASDAQ:ARIA) www.mysmartrend.com - September 15 at 12:27 PM
	ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia (NASDAQ:ARIA) www.businesswire.com - September 15 at 12:27 PM
	ARIAD Pharmaceuticals Reaches Analyst Target Price (NASDAQ:ARIA) www.forbes.com - September 15 at 12:27 PM
	Shares Climbing Higher Session: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Post News (NASDAQ:ARIA) www.kentuckypostnews.com - September 14 at 3:34 PM
	Shares Holding Above Moving Averages: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Post News (NASDAQ:ARIA) www.kentuckypostnews.com - September 14 at 3:34 PM
	Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) Downward Trend - Live Trading News (NASDAQ:ARIA) www.livetradingnews.com - September 14 at 3:34 PM
	Ariad Pharmaceuticals Leading Biotechs Higher (NASDAQ:ARIA) finance.yahoo.com - September 14 at 3:34 PM
	Analysts Valuations For Two Stocks: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), FireEye Inc (NASDAQ:FEYE) - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 13 at 8:23 AM
	Hot Biotech Stocks Recap: CytRx Corporation (NASDAQ:CYTR), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 13 at 8:23 AM
	Last-minute call buyers pile into Ariad (NASDAQ:ARIA) finance.yahoo.com - September 12 at 3:32 PM
	Watch These 7 Huge Call Purchases In Monday Trade - Benzinga (NASDAQ:ARIA) www.benzinga.com - September 12 at 8:22 AM
	HC Stocks Review= Ariad Pharmaceuticals, Inc. (ARIA), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NASDAQ:ARIA) sharemarketupdates.com - September 12 at 8:22 AM
	Experts Views on Investment Luring Stocks- Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Synergy Pharmaceuticals, Inc ... - Seneca Globe (NASDAQ:ARIA) www.senecaglobe.com - September 10 at 3:31 PM
	Stocks Focus in Frontline Brokers- Ariad Pharmaceuticals Inc ... - Seneca Globe (NASDAQ:ARIA) www.senecaglobe.com - September 9 at 3:33 PM
	Biotech news that matter for investors: Ariad Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 8 at 3:31 PM
	Trending Biotechnology Stocks Analyst Review: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Peregrine ... - Post Registrar (NASDAQ:ARIA) postregistrar.com - September 7 at 3:34 PM
	Trending Biotechnology Stocks Analyst Review: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Peregrine ... - Post Registrar (NASDAQ:ARIA) postregistrar.com - September 7 at 3:34 PM
	ETF’s with exposure to ARIAD Pharmaceuticals, Inc. : September 7, 2016 (NASDAQ:ARIA) www.capitalcube.com - September 7 at 12:40 PM
	This Expected News Sent PDL BioPharma Inc. Down 17% in August (NASDAQ:ARIA) www.fool.com - September 7 at 12:40 PM
	Incyte’s Profitability Improves, Allowing for Revised Guidance (NASDAQ:ARIA) marketrealist.com - September 5 at 3:34 PM
	Incyte’s Profitability Improves, Allowing for Revised Guidance (NASDAQ:ARIA) marketrealist.com - September 5 at 3:34 PM
	Analysts Valuations For Two Stocks: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Cloud Peak Energy Inc. (NYSE:CLD) - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 5 at 8:25 AM
	HC Stocks Assessment- Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) (NASDAQ:ARIA) sharemarketupdates.com - September 3 at 8:25 AM
	Analysts Valuations For Two Stocks: Hain Celestial Group Inc (NASDAQ:HAIN), Ariad Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 2 at 3:35 PM
	Hot Biotech Stocks Recap: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Threshold Pharmaceuticals Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ARIA) voiceregistrar.com - September 2 at 3:35 PM
	Is Incyte Hurt by Having Only One FDA-Approved Drug? (NASDAQ:ARIA) marketrealist.com - September 2 at 3:35 PM
	Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Puts Brigatinib Ball In FDA's Court - Market Exclusive (NASDAQ:ARIA) marketexclusive.com - September 1 at 11:59 AM